Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting
- Wednesday, December 15, 2021, 7:04
- Finance
- Add a comment
– Treatment with intravenous pelareorep plus azacitidine reduced tumor burden – Treatment with pelareorep and azacitidine dramatically upregulated multiple genes known to drive anti-cancer immune responses SAN DIEGO and CALGARY, AB, Dec. 15, 2021 /PRNewswire/ — Oncolytics Biotech® Inc….
About the Author
adminasapcorp has written 42014 stories on this site.